Neural mechanisms and management of obesity-related hypertension

被引:28
|
作者
Esler M.D. [1 ]
Eikelis N. [1 ]
Lambert E. [1 ]
Straznicky N. [1 ]
机构
[1] Baker IDI Heart and Diabetes Institute, Melbourne, VIC 8008, St. Kilda Road Central
关键词
Obstructive Sleep Apnea; Essential Hypertension; Sympathetic Nerve; Sympathetic Nervous Activity; Human Obesity;
D O I
10.1007/s11886-008-0072-7
中图分类号
学科分类号
摘要
The sympathetic nervous system is activated in human obesity and in the analogous experimental obesity produced by overfeeding. The causes remain uncertain and may be multiple. The consequences include hypertension, probably attributable to activation of the sympathetic outflow to the kidneys, and, more disputed, insulin resistance. The pattern of sympathetic activation in normal-weight and obesity-related hypertension differs in terms of the firing characteristics of individual sympathetic fibers (increased rate of nerve firing in normal-weight hypertensives, increased number of active fibers firing at a normal rate in obesity-hypertension) and the sympathetic outflows involved. The underlying mechanisms and the adverse consequences of the two modes of sympathetic activation may differ. Should antihypertensive drug therapy in obesity-hypertension specifically target the existing neural pathophysiology? Such an approach can be advocated on theoretical grounds. Perhaps more important is the requirement that chosen antihypertensives do not cause weight gain or insulin resistance. © Current Medicine Group LLC 2008.
引用
收藏
页码:456 / 463
页数:7
相关论文
共 50 条
  • [41] Mechanisms Underlying Obesity-Related Hypertension: An Experimental Weight Gain Study in Humans
    McEniery, Carmel M.
    Middlemiss, Jessica
    Maki-Petaja, Kaisa
    Wilkinson, Ian
    FASEB JOURNAL, 2019, 33
  • [42] Adrenergic and reflex abnormalities in obesity-related hypertension
    Grassi, G
    Seravalle, G
    Dell'Oro, R
    Turri, C
    Bolla, GB
    Mancia, G
    HYPERTENSION, 2000, 36 (04) : 538 - 542
  • [43] Hydralazine as antihypertensive therapy in obesity-related hypertension
    Carroll, JF
    King, JW
    Cohen, JS
    INTERNATIONAL JOURNAL OF OBESITY, 2004, 28 (03) : 384 - 390
  • [44] Treatment of Obesity-Related Hypertension in Children and Adolescents
    Halbach, Susan M.
    Flynn, Joseph
    CURRENT HYPERTENSION REPORTS, 2013, 15 (03) : 224 - 231
  • [45] Cardiac transcriptome analysis in obesity-related hypertension
    Philip-Couderc, P
    Smih, F
    Pelat, M
    Vidal, C
    Verwaerde, P
    Pathak, A
    Buys, S
    Galinier, M
    Senard, JM
    Rouet, P
    HYPERTENSION, 2003, 41 (03) : 414 - 421
  • [46] Adiponectin replenishment ameliorates obesity-related hypertension
    Ohashi, Koji
    Kihara, Shinji
    Ouchi, Noriyuki
    Kumada, Masahiro
    Fujita, Koichi
    Hiuge, Aki
    Hibuse, Toshiyuki
    Ryo, Miwa
    Nishizawa, Hitoshi
    Maeda, Norikazu
    Maeda, Kazuhisa
    Shibata, Rei
    Walsh, Kenneth
    Funahashi, Tohru
    Shimomura, Iichiro
    HYPERTENSION, 2006, 47 (06) : 1108 - 1116
  • [47] Recent developments in the treatment of obesity-related hypertension
    Pischon, T
    Sharma, AM
    CURRENT OPINION IN NEPHROLOGY AND HYPERTENSION, 2002, 11 (05): : 497 - 502
  • [48] Hydralazine as antihypertensive therapy in obesity-related hypertension
    J F Carroll
    J W King
    J S Cohen
    International Journal of Obesity, 2004, 28 : 384 - 390
  • [49] Treatment of Obesity-Related Hypertension in Children and Adolescents
    Susan M. Halbach
    Joseph Flynn
    Current Hypertension Reports, 2013, 15 : 224 - 231
  • [50] Effect of diabetes and hypertension on obesity-related mortality
    Livingston, EH
    Ko, CY
    SURGERY, 2005, 137 (01) : 16 - 25